Oxcarbazepine (Epilepsy)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Samrén (Oxcarbazepine), 1999 Hvas (Oxcarbazepine) (Controls unexposed, sick), 2000 Kaaja (Oxcarbazepine), 2003 Artama (Oxcarbazepine), 2005 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 Morrow (Oxcarbazepine) (Controls unexposed, sick), 2006 Hernández-Díaz (Oxcarbazepine) (Controls unexposed, disease free), 2012 Veiby (Oxcarbazepine) (Controls unexposed, sick), 2014 Tomson (Oxcarbazepine) , 2018 Vajda (Oxcarbazepine) (Controls unexposed, sick), 2019 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Hosny (Oxcarbazepine) (Controls unexposed, sick), 2021 Cohen (Oxcarbazepine) (Epilepsy) (Controls unexposed, NOS), 2023 141.49[1.19; 1.87]148,2812,102probable Major congenital malformations Samrén (Oxcarbazepine), 1999 Hvas (Oxcarbazepine) (Controls unexposed, sick), 2000 Kaaja (Oxcarbazepine), 2003 Morrow (Oxcarbazepine) (Controls unexposed, sick), 2006 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 Hernández-Díaz (Oxcarbazepine) (Controls unexposed, disease free), 2012 Veiby (Oxcarbazepine) (Controls unexposed, sick), 2014 Tomson (Oxcarbazepine) , 2018 Vajda (Oxcarbazepine) (Controls unexposed, sick), 2019 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Hosny (Oxcarbazepine) (Controls unexposed, sick), 2021 Cohen (Oxcarbazepine) (Epilepsy) (Controls unexposed, NOS), 2023 121.51[1.17; 1.96]148,2541,999critical Congenital heart defects Artama (Oxcarbazepine), 2005 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Tomson (Oxcarbazepine) , 2018 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 41.93[0.87; 4.24]42510not evaluable Limb defects Artama (Oxcarbazepine), 2005 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 32.81[0.46; 17.19]12177not evaluable Spina bifida Artama (Oxcarbazepine), 2005 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 Veiby (Oxcarbazepine) (Controls unexposed, sick), 2014 313.65[1.72; 108.21]3152not evaluable Urinary malformations Artama (Oxcarbazepine), 2005 Tomson (Oxcarbazepine) , 2018 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 30.92[0.20; 4.14]16503not evaluable Digestive system anomalies Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 25.01[0.55; 45.94]478not evaluable Cleft lip with or without cleft palate Artama (Oxcarbazepine), 2005 Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 25.45[0.36; 83.53]2101not evaluable Hypospadias Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Tomson (Oxcarbazepine) , 2018 22.04[0.16; 25.25]12340not evaluable Nervous system anomalies Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 14.82[0.09; 244.75]-71not evaluable Neural Tube Defects Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Tomson (Oxcarbazepine) , 2018 28.87[0.71; 110.59]2340not evaluable Oro-facial clefts Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Tomson (Oxcarbazepine) , 2018 26.85[0.59; 80.08]5340not evaluable Polydactyly Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 Tomson (Oxcarbazepine) , 2018 226.41[2.05; 340.38]1335not evaluable Chromosomal abnormalities Artama (Oxcarbazepine), 2005 19.53[0.19; 482.86]-99not evaluable Cleft palate Viinikainen (Oxcarbazepine) (Controls unexposed, sick) a, 2006 134.33[0.49; 2389.88]-2not evaluable Ear, face and neck anomalies Artama (Oxcarbazepine), 2005 11.90[0.09; 39.89]299not evaluable Eye defects Artama (Oxcarbazepine), 2005 13.17[0.13; 78.41]199not evaluable Genital anomalies Artama (Oxcarbazepine), 2005 11.91[0.22; 16.48]699not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 41.16[0.88; 1.53]251,970674not evaluable Small for gestational age (weight) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Dreier (Oxcarbazepine), 2021 51.37[1.12; 1.67]209,0952,133not evaluable Low birth weight (< 2500g) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 21.29[0.90; 1.85]91,551670not evaluable Large for gestational age (weight) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 20.78[0.26; 2.30]86531not evaluable Macrosomia (> 4000g) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 10.79[0.55; 1.13]577,138143not evaluable Very preterm (28 to 32 weeks) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 10.70[0.04; 11.18]8,584143not evaluable Extremely preterm (< 28 weeks) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 15.89[0.82; 42.16]2,042143not evaluable Maternal consequences Preeclampsia Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 21.61[0.75; 3.47]53,6254not evaluable Caesarean Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 10.98[0.76; 1.27]430532not evaluable Abruptio placentae (retroplacental hematoma) Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 11.34[0.26; 6.90]20,260-not evaluable Amniotic fluid problems (polyhydramnios and/or oligohydramnios) Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 16.14[0.10; 363.16]-4not evaluable Gestational diabetes Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 11.95[0.07; 58.24]14not evaluable Neonatal disorders Neonatal medical care Viinikainen (Oxcarbazepine) (Controls unexposed, disease free) a, 2006 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 33.13[0.43; 22.52]2,025471not evaluable Low Apgar score (< 7) (at 1 min) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 11.33[0.83; 2.13]96465not evaluable Low Apgar score (< 7) (at 5 min) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 10.70[0.14; 3.49]5230not evaluable Neonatal disorders (as a whole) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 10.90[0.54; 1.50]222,218143not evaluable Long term consequences Child/Infant death (> 28 days of life) Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 21.87[0.52; 6.65]4,704670not evaluable Behavioral disorders Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 11.09[0.59; 2.02]1301,460not evaluable Emotional disorders Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 10.88[0.47; 1.65]831,460not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Tomson (Oxcarbazepine), 2015 Vajda (Oxcarbazepine) (Controls unexposed, sick), 2018 Trivedi (Oxcarbazepine) (Controls unexposed, sick), 2018 33.13[0.62; 15.80]184337not evaluable Late intrauterine deaths (> 22 weeks) Tomson (Oxcarbazepine), 2015 AlSheikh (Oxcarbazepine) (Controls unexposed, sick), 2020 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 32.79[0.68; 11.38]8269not evaluable Perinatal death Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Tomson (Oxcarbazepine), 2015 22.56[0.96; 6.84]20772not evaluable Elective/induced termination of pregnancy Hosny (Oxcarbazepine) (Controls unexposed, sick), 2021 18.20[0.13; 511.93]-3not evaluable Early intrauterine death (< 22 weeks) Tomson (Oxcarbazepine), 2015 11.01[0.62; 1.65]164262not evaluable Neuro-developmental disorders ASD (Autism spectrum disorder): Diagnosis/Risk Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 31.24[0.82; 1.87]4,6621,607not evaluable Language disorders/delay Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Meador (Oxcarbazepine) (Controls unexposed, disease free), 2021 32.52[0.94; 6.73]72,025166not evaluable ASD (Autism spectrum disorder): Diagnosis Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 21.24[0.82; 1.87]4,6351,603not evaluable Neuro-developmental disorders (as a whole) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2022 20.96[0.68; 1.36]10,4451,572not evaluable ASD (Autism spectrum disorder): Risk Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 11.27[0.06; 25.24]274not evaluable Cognitive developmental disorders/delay (3-6 years old) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 11.76[0.11; 28.32]3,398143not evaluable Severe cognitive developmental delay (Mental retardation) (3-6 years old) Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 11.76[0.11; 28.32]3,398143not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 10.99[0.70; 1.40]5801,460not evaluable ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 10.99[0.70; 1.40]5801,460not evaluable Cognitive developmental disorders/delay (< 3 years old) Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 15.76[1.65; 20.13]-10not evaluable Cognitive developmental disorders/delay (> 6 years old) Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 11.15[0.70; 1.88]2081,460not evaluable Psychomotor developmental disorders/delay Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 12.33[0.69; 7.90]-10not evaluable Severe cognitive developmental delay (Mental retardation) (> 6 years old) Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 11.15[0.70; 1.88]2081,460not evaluable Learning disorders Elkjaer (Oxcarbazepine), 2018 11.06[1.01; 1.12]-124not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons